Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Open-label Phase II Efficacy Study of Repotrectinib in Frail (PS ≥2) and/or Elderly Patients With ROS1-rearranged Advanced NSCLC

NCT06552234 is registered in ClinicalTrials.gov with Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer as lead sponsor.

NCT NCT06552234
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06552234 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Open-label Phase II Efficacy Study of Repotrectinib in Frail (PS ≥2) and/or Elderly Patients With ROS1-rearranged Advanced NSCLC
Lead sponsor
Centre Hospitalier Intercommunal de Toulon La Seyne sur Mer
Phase
Phase 2
Overall status
Recruiting
Start date
October 1, 2024
Completion date
September 30, 2031
Enrollment
30 (estimated)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

nsclc stage iv, nsclc, stage iii